Zasocitinib IR Event Phase 3 Psoriasis Data Presented at AAD

from the beginning

Zasocitinib IR Event Phase 3 Psoriasis Data Presented at AAD

Important Notice

Opening Remarks

Preparing to launch 3 transformative medicines in the next 15 monthssetting Takeda on a new growth trajectory

Zasocitinib: Poised to be a leading oral treatment option forpatients with psoriasis - significantly expanding the oral market

Zasocitinib Phase 3 Psoriasis Results

Zasocitinib: Next-generation, highly selective oral TYK2 inhibitor

LATITUDE-PsO-3001 and 3002 were randomized, multicenter, double-blind, placebo- and apremilast-controlled phase 3 trials

Baseline demographics and characteristics were generally similar across treatment arms in each study

Zasocitinib met the co-primary endpoints in both studies(sPGA0/1 and PASI 75 versus placebo at Week 16)

Rapid skin clearance as early as week 4 with zasocitinib

Zasocitinib led to greater proportions of patients achievingPASI 90 than apremilast or placebo as early as Week 4

Zasocitinib led to greater proportions of patients achievingclear skin versus apremilast or placebo as early as Week 8(1)

Zasocitinib led to greater proportions of patients achievingclear skin versus apremilast or placebo as early as Week 8(2)

Zasocitinib demonstrated superior improvement in DLQI versus apremilast or placebo as early as Week 4

Zasocitinib was well tolerated with no new safety signals identified through Week 16

LATITUDE-PsO-3001 and 3002 were randomized, multicenter, double-blind, placebo- and apremilast-controlled phase 3 trials

More than 90% of patients continuing zasocitinib at Week 40 maintained sPGA 0/1, PASI 75 and PASI 90 through Week 60

Zasocitinib: Enabling expansion with focused LCM programs

Zasocitinib: Rapid and durable skin clearance in a convenient once-daily pill

Zasocitinib Market Opportunity & Commercialization

Transformational efficacy with next-generation orals can give patients an opportunity to achieve clear skin without proceeding to biologics

Zasocitinib: Meeting patient needs with a treatment that fits effortlessly into daily life

Takeda’s proven immunology leadership positions it to execute a successful zasocitinib launch

Zasocitinib is positioned to transform and expand the oral advanced therapy market in psoriatic disease

Zasocitinib: Poised to be a leading oral treatment option forpatients with psoriasis - significantly expanding the oral market

Q&A Session

• Q&A Session1

• Q&A Session2

• Q&A Session3

• Q&A Session4

• Q&A Session5

• Q&A Session6

Medical Presentationas presented at AAD 2026

Once-daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)

Disclosures

Zasocitinib is an investigational, oral, allosteric, highly selective and potent TYK2 inhibitor

LATITUDE-PsO-3001 and 3002 were randomized, multicenter, double-blind, placebo- and apremilast-controlled phase 3 trials(1)

LATITUDE-PsO-3001 and 3002 were randomized, multicenter, double-blind, placebo- and apremilast-controlled phase 3 trials(2)

Baseline demographics and characteristics were generally similar across treatment arms in each study

Zasocitinib met the co-primary endpoints in both studies (sPGA 0/1 and PASI 75 versus placebo at Week 16)(1)

Zasocitinib met the co-primary endpoints in both studies (sPGA 0/1 and PASI 75 versus placebo at Week 16)(2)

Zasocitinib led to greater proportions of patients achieving PASI 90 than apremilast or placebo as early as Week 4(1)

Zasocitinib led to greater proportions of patients achieving PASI 90 than apremilast or placebo as early as Week 4(2)

Zasocitinib led to greater proportions of patients achieving clear skin versus apremilast or placebo as early as Week 8(1)

Zasocitinib led to greater proportions of patients achieving clear skin versus apremilast or placebo as early as Week 8(2)

Zasocitinib demonstrated superior improvement in DLQI versus apremilast or placebo as early as Week 4

Zasocitinib was well tolerated with no new safety signals identified through Week 24

More than 90% of patients continuing zasocitinib at Week 40 maintained sPGA 0/1, PASI 75 and PASI 90 through Week 60

Conclusions

Acknowledgments